Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meal-time Administration of exenatide for Glycaemic control in type 1 diabetic Cases: A randomised, placebo-controlled trial

Next Previous
X
Search
Trial Profile

Meal-time Administration of exenatide for Glycaemic control in type 1 diabetic Cases: A randomised, placebo-controlled trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms MAG1C

    • Most Recent Events

    • 26 Jun 2023 Results of a post-hoc analysis assessing fatty liver index of short-acting exenatide 10 microgm added three times daily to insulin therapy over 26 weeks of treatment presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 07 Jun 2022 Results of a post-hoc analysis assessing estimated glucose disposal rate through week 26 presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
    • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top